Syros PharmaceuticalsSYRS
13F holders, Q1 2025 (March 31)7holders −37
1new positions
38sold out
$0.03avg. 13F price*
At the end of Q1 2025, 7 institutions reported holding Syros Pharmaceuticals Inc. (SYRS) in their 13F filings, down 37 from Q4 2024. 1 opened new positions and 38 sold out. The largest holders were Acadian Asset Management LLC ($9K), Baader Bank Aktiengesellschaft ($2K) and 1492 Capital Management LLC ($1K).
- Company
- Syros Pharmaceuticals Inc.
- CUSIP
- 87184Q206
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 38 | $1.1M |
All 13F filers, Q4 2024 → Q1 2025: 157,262 shares bought and 4,907,577 shares sold, net −4,750,315 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Acadian Asset Management LLC | 0.00% | Add +32.2% | 329,793 | $9K |
| Baader Bank Aktiengesellschaft | 0.00% | Add +279.6% | 83,864 | $2K |
| 1492 Capital Management LLC | 0.00% | No change | 39,244 | $1K |
| XTX Topco Ltd | 0.00% | Reduce -87.7% | 10,053 | $290 |
| Simplex Trading, LLC | 0.00% | New | 4,123 | $0 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 8 | $0 |
| FNY Investment Advisers, LLC | 0.00% | Add +215.7% | 16,100 | $0 |
"% of holder's portfolio" is SYRS's weight in each manager's 13F, not the share of Syros Pharmaceuticals Inc. the manager owns.